Tardive dyskinesia is most strongly associated with long-term use of antipsychotic medications, particularly older drugs like haloperidol and chlorpromazine. But antipsychotics aren’t the only culprit. Any medication that blocks dopamine receptors in the brain can cause this movement disorder when taken over months or years, including some common anti-nausea drugs.
First-Generation Antipsychotics Carry the Highest Risk
The medications most closely linked to tardive dyskinesia are first-generation (also called “typical”) antipsychotics. These include haloperidol (Haldol), chlorpromazine (Thorazine), fluphenazine, and perphenazine. They work by strongly blocking dopamine receptors in the brain, which helps control symptoms of schizophrenia and other psychotic disorders but also disrupts normal movement signaling over time.
First-generation antipsychotics cause tardive dyskinesia at a rate of roughly 5% per year in adults. That means after five years of continuous use, about one in four patients may develop symptoms. Haloperidol specifically has been studied in randomized trials and shows a yearly risk of about 5.4%, though one study of patients on low-dose haloperidol found a 12-month incidence as high as 12.3%. For older adults, the numbers are significantly worse: 25% to 30% per year. Overall, meta-analyses estimate that about 25.3% of people treated with first-generation antipsychotics will develop tardive dyskinesia at some point during treatment.
Second-Generation Antipsychotics Still Pose a Risk
When newer “atypical” antipsychotics like risperidone (Risperdal), olanzapine (Zyprexa), quetiapine (Seroquel), and aripiprazole (Abilify) were introduced, they were expected to largely eliminate the tardive dyskinesia problem. The risk is lower, but it hasn’t disappeared. A large meta-analysis found a pooled prevalence of 13.1% among people on second-generation antipsychotics, roughly half the rate seen with older drugs.
In prospective studies, after adjusting for other factors, people on atypical antipsychotics alone developed tardive dyskinesia at about two-thirds the rate of those on conventional antipsychotics. Olanzapine appeared to carry a somewhat lower risk, while risperidone’s rate was closer to that of older drugs. One particularly concerning finding: patients who took both old and new antipsychotics together developed tardive dyskinesia at nearly double the rate of those on conventional drugs alone.
Metoclopramide: A Widely Prescribed Non-Psychiatric Cause
Metoclopramide (Reglan) is one of the most common non-psychiatric medications linked to tardive dyskinesia. It’s prescribed for nausea, vomiting, gastroparesis, and acid reflux. Like antipsychotics, it blocks dopamine receptors, though patients often don’t realize they’re taking a drug with this mechanism.
The risk is serious enough that the FDA requires a black box warning on metoclopramide, its strongest safety alert. The label states explicitly that tardive dyskinesia risk increases with treatment duration and total cumulative dose, and that treatment beyond 12 weeks should be avoided except in rare cases where the benefit clearly outweighs the risk. Despite this warning, many patients end up on metoclopramide for months or years, particularly for chronic digestive conditions.
Other Dopamine-Blocking Medications
Prochlorperazine (Compazine) is another anti-nausea medication that can cause tardive dyskinesia with long-term use. It belongs to the phenothiazine class, the same chemical family as some older antipsychotics, and works by blocking dopamine receptors in the brain. While cases are considered rare, they are documented, and the risk exists with prolonged use. Alternative anti-nausea medications that work through different pathways, such as ondansetron (Zofran), do not carry this risk.
Promethazine (Phenergan), used for nausea and allergies, also has dopamine-blocking activity and has been linked to tardive dyskinesia in case reports. Other less common culprits include certain antidepressants and lithium, though these associations are much weaker than with antipsychotics and dopamine-blocking antiemetics.
Why These Medications Cause Movement Problems
All the medications linked to tardive dyskinesia share one feature: they block dopamine receptors, particularly a type called D2 receptors, in areas of the brain that control movement. When these receptors are blocked for months or years, the brain compensates by making more of them and making the remaining ones more sensitive to dopamine. This is called receptor supersensitivity.
The result is that movement-control circuits become overactive. The brain’s normal braking system for unwanted movements essentially gets overwhelmed, leading to the involuntary repetitive movements that define tardive dyskinesia. These typically appear as lip smacking, tongue protrusion, chewing motions, or grimacing in the face, though they can also involve the arms, legs, and trunk. The word “tardive” means delayed, reflecting the fact that symptoms usually emerge only after months or years of drug exposure.
Who Faces the Greatest Risk
Not everyone on these medications develops tardive dyskinesia. Several factors increase individual susceptibility. Age is the strongest predictor. Older adults develop symptoms faster, after shorter treatment periods, and at much higher rates. Diagnostic criteria reflect this: a formal diagnosis requires at least three months of drug exposure in most adults, but only one month for people over 60.
Diabetes is another significant risk factor. In a study of 160 elderly patients starting antipsychotic treatment, those with diabetes developed tardive dyskinesia at more than twice the rate of those without it: 54.1% versus 25.6% after about 10 months. Women, people of African descent, and those with mood disorders (as opposed to schizophrenia) also appear to face elevated risk. Higher medication doses and longer treatment duration consistently increase the likelihood of developing symptoms.
How Tardive Dyskinesia Is Detected
Because tardive dyskinesia often develops gradually, it can go unnoticed for months. Clinicians use a standardized screening tool called the Abnormal Involuntary Movement Scale (AIMS), which rates involuntary movements across seven body areas: facial muscles, lips, jaw, tongue, upper limbs, lower limbs, and trunk. Each area is scored from 0 (no movement) to 4 (severe), and a total score of 2 or more across two body regions, or 3 or more in any single region, meets the threshold for a probable diagnosis. Prevalence estimates range widely from 13% to 50% depending on the population studied, partly because many cases go undetected without routine screening.
Treatment Once It Develops
Tardive dyskinesia was historically considered irreversible, and for some patients it is. Stopping the offending medication can lead to improvement, but symptoms may persist indefinitely, especially after years of exposure. In 2017, the FDA approved the first medications specifically designed to treat tardive dyskinesia. These drugs, valbenazine (Ingrezza) and deutetrabenazine (Austedo), work by reducing the amount of dopamine available in movement circuits, essentially counteracting the supersensitivity that developed during years of dopamine blockade. They don’t cure the condition but can significantly reduce involuntary movements for many patients.
The challenge is that many people who develop tardive dyskinesia still need the antipsychotic or antiemetic that caused it. Switching to a lower-risk medication, reducing the dose, or adding a targeted treatment are the typical strategies. The earlier tardive dyskinesia is caught, the better the chances of meaningful improvement.